3 news items
Zymeworks Achieves Key Milestone with BLA Acceptance for Zanidatamab in China, Zymeworks to Receive Up to $164M in Milestone Payments
ZYME
10 Jun 24
progression-free survival (PFS) assessed by independent central review (ICR) were 41.3% (95% CI: 30.4–52.8), 12.9 months (95% CI: 6.0–not estimable), and 5.5 months (95% CI: 3.7–7.2), respectively.
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
ZYME
10 Jun 24
. As of October 10, 2022, the objective response rate (ORR), median duration of response (DOR), and median progression-free survival (PFS) assessed by independent
Navigating 6 Analyst Ratings For Zymeworks
ZYME
6 Jun 24
state of the company.
Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from
- Prev
- 1
- Next